TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06564974: Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT

Sponsor: Catalyst Pharmaceuticals, Inc. · Phase: PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 250 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,965,500

Rescue Site Savings

+$2,626,500

Unlock Full NCT06564974 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06564974 Rescue Dossier →